fda compounding semaglutide update today The is proposing the removal of three GLP-1 drugs from the 503B bulks list of active ingredients that outsourcing facilities can use to make compounded medicines, the agency announced on Thursday Navigating changes in access to

Key takeaways for patients: Routine eye exams are essential

The number of queries related to the drugs more than doubled between 2024 and 2025, he says

Our semaglutide weight loss program is designed to help you achieve and maintain your weight loss goals

Orforglipron is gaining attention because it offers the benefits of GLP-1 therapy in the form of daily oral pills, which are convenient to use

By simultaneously activating GIP, GLP-1, and glucagon receptors, this powerful peptide produces synergistic metabolic effects that exceed what single or dual agonist medications can achieve

To increase the therapeutic effectiveness of GLP-1 in people with type 2 diabetes mellitus (T2DM), attempts have been made to prolong its half-life in the body